# Naveen Yalamanchi

> Naveen Yalamanchi is a Series C investor at RTW Investments backing Medical Device and Diabetes. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [RTW Investments](https://shizune.co/investors/profile/rtw-investments-llc)
- Location: New York, United States
- Total investments: 5
- Last investment: Feb 2022
- Lead investor: 80%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/naveen-yalamanchi-0037333

Naveen Yalamanchi is a Member of the Board of Directors at Rocket Pharmaceuticals.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 2 | 40% |
| Diabetes | 1 | 20% |
| Health Care | 1 | 20% |
| Biotechnology | 1 | 20% |
| Health Diagnostics | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 40% |
| Series B | 1 | 20% |
| Funding Round | 1 | 20% |
| Private Equity | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Beta Bionics | Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in aready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States. | $57M | Series C | Feb 17, 2022 |  |
| Magnolia Medical Technologies | Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests. It has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’sintellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending.It was incorporated in 2011 and is based in Seattle, Washington. |  |  | Feb 16, 2022 |  |
| Magnolia Medical Technologies | Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests. It has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’sintellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending.It was incorporated in 2011 and is based in Seattle, Washington. | $46M | Private Equity | Feb 16, 2022 |  |
| Magnolia Medical Technologies | Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests. It has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’sintellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending.It was incorporated in 2011 and is based in Seattle, Washington. | $20M | Series C | Jan 30, 2019 |  |
| Beta Bionics | Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in aready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States. | $63M | Series B | Jan 08, 2019 |  |

5 of 5 investments shown.

## Co-investors
- [ArrowMark Partners](https://shizune.co/investors/profile/arrowpoint-partners) — VC Fund, 3 deals together
- [Evidity Health Capital](https://shizune.co/investors/profile/canepa-advanced-healthcare-fund) — VC Fund, 3 deals together
- [HealthQuest Capital](https://shizune.co/investors/profile/heathquest-capital-2) — VC Fund, 3 deals together
- [Eventide](https://shizune.co/investors/profile/eventide-asset-management) — VC Fund, 2 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 2 deals together
- [LifeSci Venture Partners](https://shizune.co/investors/profile/lifesci-venture-partners) — VC Fund, 2 deals together

## About RTW Investments

VC Fund · New York, United States

RTW Investments makes investments in forward-thinking healthcare companies. It invests across the entire company lifecycle, including company creation, early-stage venture capital, alternative financing, and public company investments. The company is headquartered in New York with offices in London and Shanghai.

5 contacts available at RTW Investments.

| Name | Title | Profile |
| --- | --- | --- |
| Lauren Lee | Research Analyst | https://shizune.co/investors/profile/lauren-lee-b1a9 |
| Naveen Yalamanchi | Partner | https://shizune.co/investors/profile/naveen-yalamanchi |
| Robert Aurigema | Chief Financial Officer | https://shizune.co/investors/profile/robert-aurigema-8693 |
| Sabera Loughran | Chief Operating Officer | https://shizune.co/investors/profile/sabera-loughran-919f |
| Gaurav Shah | Entrepreneur in Residence | https://shizune.co/investors/profile/gaurav-shah-2 |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Naveen Yalamanchi invest in?

Naveen Yalamanchi invests primarily in Medical Device, Diabetes and Health Care startups, most often at Series C and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Naveen Yalamanchi last invest?

The most recent investment recorded for Naveen Yalamanchi closed in Feb 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co